Category: Media

Aurealis Therapeutics Developing a Drug Therapy with Multiple Active Substances in One Product Has Initiated Repeated Dosing Groups in the Diabetic Foot Ulcer Patient Trial

Basel Switzerland, Kuopio Finland – November 17th, 2020. Aurealis Therapeutics, a private clinical-stage biopharmaceutical company, is making a difference in chronic, non-healing wounds by developing a therapy with multiple active substances in one product that are hitting all key pathomechanisms. Chronic wound care needs curative drugs with true active pharmaceutical substances, not just incrementally improved … Continued


Read more


Aurealis Therapeutics to Strengthen Its Board of Directors by Appointing Dr. Laurent Décory, an Experienced Advanced Wound Care Industry Executive

Basel Switzerland, Kuopio Finland – June 17th, 2020. Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the four-in-one biologic drug for chronic non-healing wounds and regenerative diseases, announced today that Mr. Laurent Décory has joined the Board of Directors of the company as of June 10th, 2020. Existing Board Directors Iain Buchanan, Silvio Inderbitzin … Continued


Read more


AUREALIS THERAPEUTICS PIONEERING MULTIPLE DRUG PRODUCING BACTERIA AUP-16 DOSED TO THE FIRST DIABETIC FOOT ULCER PATIENT IN THE PHASE 1-2A TRIAL

Basel Switzerland, Kuopio Finland – February 11th, 2020. Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today that the first diabetic foot ulcer (DFU) patient has been dosed with AUP-16. The trial is performed in non-healing DFU patients and is designed … Continued


Read more


Aurealis Therapeutics Receives Clinical Trial Application Approval for AUP-16 Diabetic Foot Ulcer Patient Trial

Basel Switzerland, Kuopio Finland – September 27th, 2019. Aurealis Therapeutics, a private biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today clinical trial application (CTA) approval of the AUP-16 phase 1 diabetic foot ulcer (DFU) patient trial by the German Health Authority Paul-Ehrlich-Institute. The company plans … Continued


Read more


Aurealis Pharma Announces 7.8MCHF Financing to Advance the Chronic Wound Lead Candidate AUP-16 to Diabetic Foot Ulcer Patients under New Brand Aurealis Therapeutics AG

Press release Basel Switzerland, Kuopio Finland – February 8th, 2019.Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced 7.8MCHF funding provided by Swiss and foreign private investors, Finnvera plc, and Business Finland – the Finnish Innovation Funding Agency. The Company also confirmed the de-merger and a … Continued


Read more


Aurealis Pharma Submitted Clinical Trial Application for First-in-Human Phase 1-2A Clinical Study to German Health Authority Paul-Ehrlich-Institute (PEI)

Press Release Basel Switzerland, Kuopio Finland – October 15th, 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced today the successful submission of its first Clinical Trial Application to the German Health Authority Paul-Ehrlich-Institute (PEI) for the lead development candidate AUP1602-C to be studied in … Continued


Read more


Aurealis Pharma to Strengthen It´s Board of Directors by Appointing Mr. Iain Buchanan, a Seasoned Biotech and Pharma Industry Executive

Press Release Basel Switzerland, Kuopio Finland – May 22nd 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that Mr. Iain Buchanan has joined the board of directors of the company as of May 16th 2018. Existing board members CSO and founder Mr. … Continued


Read more


Aurealis Pharma To Present at the European Wound Management Association (EWMA) Congress 2018 in Krakow, Poland, May 9th – 11th 2018

Press Release Basel Switzerland, Kuopio Finland – April 30th 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CMO Dirk Weber will attend and discuss the company´s progress and clinical development plans for lead development product AUP-16 indicated for chronic wounds at … Continued


Read more


Aurealis Pharma To Attend The Swiss Biotech Day in Basel, May 3rd 2018

Press Release Basel Switzerland, Kuopio Finland – April 26th 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki and CMO Dirk Weber will attend and discuss the company´s progress at the Swiss Biotech Day in Basel on May 3rd … Continued


Read more


Aurealis Pharma To Present at the 11th Annual European Life Sciences CEO Forum & Exhibition in Zurich, February 26-27th 2018

Press Release Basel Switzerland, Kuopio Finland – February 19th 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki will attend and present the company´s progress at the 11th Annual European Life Sciences CEO Forum & Exhibition in Zurich on … Continued


Read more